Skip to content Skip to footer
Vivos Stock

Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds

February 15, 2024 08:00 ET| Source: Vivos Therapeutics, Inc LITTLETON, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea…

Read More

CPAP Recall Alert - Vivos Therapeutics

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

United Healthcare Updated Medical Policy Favoring Oral Appliance Therapies and Recent Recalls of Many ResMed and Philips Respironics' CPAP Devices Create Significant Revenue Opportunities for Vivos Devices February 06, 2024 07:30 ET| Source: Vivos Therapeutics, Inc LITTLETON, Colo., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and…

Read More

Vivos mmRNA appliance

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA

New Dentist Inquiries Jumped 600% and Signed Dentist Enrollment Contracts up 38% Sequentially Over Q3 CARE Oral Medical Device Unit Orders Increased 26% Following FDA Clearance LITTLETON, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly…

Read More

Women's Sleep & Airway Collective - Champions of Airway

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Vivos unites influential women leaders in medicine and dentistry to drive collaboration following first ever FDA 510(k) clearance of an oral device to treat severe OSA December 11, 2023 07:30 ET | Source: Vivos Therapeutics, Inc LITTLETON, Colo., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical…

Read More

Vivos DNA appliance

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for Vivos   LITTLETON, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and…

Read More

Vivos 2023 Q3 Financial Summary and Operational Update

Vivos Reports 2023 Q3 Financial Results and Operational Update

November 14, 2023 16:05 ET | Source: Vivos Therapeutics, Inc Follow Operating Expenses Decreased 32% Year Over Year and 19% Sequentially as Cost Cutting Measures Take Hold New Strategic Relationships, Including U.S. Nationwide Distribution Agreement with Lincare, Expected to Add Potentially Significant New Revenue Opportunities Management to Host Conference Call Today at 5:00…

Read More

Lincare A Linde Company

Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare

Lincare to distribute Vivos oral appliances through an exclusive nationwide agreement October 24, 2023 07:30 ET | Source: Vivos Therapeutics, Inc Follow LITTLETON, Colo., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS a leading medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate…

Read More

Stanford Medicine

Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

Randomized controlled clinical trial using Vivos’ DNA Oral Appliance Therapy to study the DNA’s impact on OSA versus CPAP October 11, 2023 07:30 ET | Source: Vivos Therapeutics, Inc LITTLETON, Colo., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company") (NASDAQ: VVOS), a medical technology company focused on developing innovative…

Read More

Vivos Announces Collaboration to Support International Expansion

Vivos Announces Collaboration in the Middle East North Africa to Support International Expansion

October 05, 2023 07:30 ET | Source: Vivos Therapeutics, Inc Vivos Executes Distribution Agreement with Established Dubai-based Sleep Testing Company Subject to Regulatory Approvals, Vivos Could See Revenue From This Collaboration in 2024 LITTLETON, Colo., Oct. 05, 2023 (GLOBE NEWSWIRE) --  Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing…

Read More